Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2022

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of September 30, 2022 and December 31, 2021 were as follows:


	September 30, 2022		December 31, 2021
Accrued compensation expenses	$	296,655	$	508,343
Accrued research and development		764,296		229,090
Accrued professional fees		115,189		43,102
Other accounts payable and accrued expenses		5,940		63,374
Total	$	1,182,080	$	843,909